Wave Life Sciences (WVE) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
108.3M
Operating Income
-110.4M
-101.94%
Net Income
-97.0M
-89.57%
EPS (Diluted)
-$0.70
Balance Sheet Metrics
Total Assets
352.2M
Total Liabilities
142.7M
Shareholders Equity
209.5M
Debt to Equity
0.68
Cash Flow Metrics
Operating Cash Flow
-155.6M
Free Cash Flow
-152.0M
Revenue & Profitability Trend
Wave Life Sciences Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 108.3M | 113.3M | 3.6M | 41.0M | 20.1M |
| Cost of Goods Sold | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | 218.7M | 181.3M | 166.4M | 168.0M | 173.5M |
| Operating Income | -110.4M | -68.0M | -162.7M | -127.0M | -153.4M |
| Pre-tax Income | -97.0M | -58.2M | -161.1M | -122.4M | -150.8M |
| Income Tax | 0 | -677.0K | 681.0K | -204.0K | -841.0K |
| Net Income | -97.0M | -57.5M | -161.8M | -122.2M | -149.9M |
| EPS (Diluted) | -$0.70 | -$0.54 | -$2.05 | -$2.36 | -$3.82 |
Income Statement Trend
Wave Life Sciences Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 320.4M | 235.4M | 98.5M | 162.6M | 230.0M |
| Non-Current Assets | 31.8M | 39.6M | 47.8M | 44.4M | 49.2M |
| Total Assets | 352.2M | 274.9M | 146.4M | 207.0M | 279.2M |
| Liabilities | |||||
| Current Liabilities | 111.0M | 186.4M | 71.5M | 64.2M | 121.0M |
| Non-Current Liabilities | 31.7M | 48.9M | 120.0M | 110.3M | 75.4M |
| Total Liabilities | 142.7M | 235.3M | 191.5M | 174.5M | 196.5M |
| Equity | |||||
| Total Shareholders Equity | 209.5M | 39.6M | -45.1M | 32.5M | 82.8M |
Balance Sheet Composition
Wave Life Sciences Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -97.0M | -57.5M | -161.8M | -122.2M | -149.9M |
| Operating Cash Flow | -155.6M | -16.7M | -129.1M | -95.7M | -111.0M |
| Investing Activities | |||||
| Capital Expenditures | -938.0K | -1.1M | -1.3M | -560.0K | -1.3M |
| Investing Cash Flow | -938.0K | -1.1M | -1.3M | -560.0K | -1.3M |
| Financing Activities | |||||
| Dividends Paid | - | - | - | - | - |
| Financing Cash Flow | 236.2M | 131.3M | 52.3M | 55.0M | 153.6M |
| Free Cash Flow | -152.0M | -20.5M | -129.1M | -89.6M | -117.3M |
Cash Flow Trend
Wave Life Sciences Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-9.80
Forward P/E
-7.10
Price to Book
6.24
Price to Sales
10.22
PEG Ratio
-7.10
Profitability Ratios
Profit Margin
-107.04%
Operating Margin
-542.82%
Return on Equity
-105.50%
Return on Assets
-30.02%
Financial Health
Current Ratio
2.95
Debt to Equity
13.13
Beta
-1.05
Per Share Data
EPS (TTM)
-$0.75
Book Value per Share
$1.12
Revenue per Share
$0.72
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| wve | 1.1B | -9.80 | 6.24 | -105.50% | -107.04% | 13.13 |
| Vertex | 114.1B | 32.82 | 6.92 | -5.64% | -8.91% | 10.00 |
| Regeneron | 55.3B | 13.02 | 1.84 | 15.96% | 31.94% | 9.20 |
| Vera Therapeutics | 1.4B | -8.41 | 2.58 | -39.49% | 0.00% | 10.18 |
| Immunocore Holdings | 1.6B | -31.41 | 4.13 | -5.86% | -6.48% | 114.67 |
| Agios | 1.9B | 2.89 | 1.32 | 60.26% | 1,798.26% | 3.61 |
Financial data is updated regularly. All figures are in the company's reporting currency.